Tanshinone IIA in Acute Promyelocytic Leukemia

被引:10
|
作者
Li, Jian
Zhang, Kaiji
Meng, Wentong [2 ]
Yang, Yiming [1 ]
机构
[1] Sichuan Univ, W China Med Sch, Dept Hematol, Chengdu 610041, Sichuan Provinc, Peoples R China
[2] Sichuan Univ, Lab Stem Cell Biol, State Key Lab Biotherapy, Chengdu 610041, Sichuan Provinc, Peoples R China
来源
关键词
Tanshinone IIA; MR2; cell; Apoptosis; Acute promyelocytic leukemia; TRANS-RETINOIC ACID; GROWTH-INHIBITION; CELL-LINE; IN-VITRO; APOPTOSIS INDUCTION; ACTIVATION; MATURATION; RECEPTORS; CANCER; ALPHA;
D O I
10.1097/MAJ.0b013e318240bca6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The prognosis of acute promyelocytic leukemia (APL) has been significantly improved by the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, the utility of these drugs is limited by resistance to ATRA and the side effects of ATO. It has been reported that Tanshinone IIA (Tan IIA), a diterpene quinone isolated from Salvia Miltiorrhiza Bunge, induces apoptosis in the APL cell line, NB4. The effect of Tan IIA on the ATRA-resistant APL cell line (MR2) is unknown. Methods: In this study, the effects of Tan IIA and ATO, alone and in combination, on MR2 cell apoptosis were investigated using transmission electron microscopy, flow cytom-etry and Western blot analyses. Results: Nuclear changes typical of apoptosis were observed in Tan IIA-treated MR2 cells. Apoptosis was shown to be induced in a dose-and time-dependent manner with the activation of caspase-3 resulting in upregulation of tumor necrosis factor-a expression, activation of caspase-8 and alteration in mitochondrial transmembrane potential with release of cytochrome c (cyto-c). Tan IIA and ATO acted synergistically on the induction of MR2 cell apoptosis. Conclusions: These data indicate that Tan IIA may be beneficial in the treatment of ATRA-resistant APL and in combination with ATO for APL therapy in the clinic.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 50 条
  • [31] ACUTE PROMYELOCYTIC LEUKEMIA WITH HYPOFIBRINOGENEMIA
    LAWS, WC
    BOHANNON, RA
    ROBINSON, AJ
    AGGELER, PM
    CALIFORNIA MEDICINE, 1968, 109 (03): : 219 - &
  • [32] EPIDEMIOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
    MELE, A
    STAZI, MA
    PULSONI, A
    VISANI, G
    MONARCA, B
    CASTELLI, G
    ROCCHI, L
    AVVISATI, G
    MANDELLI, F
    HAEMATOLOGICA, 1995, 80 (05) : 405 - 408
  • [33] Extramedullary acute promyelocytic leukemia
    Benekli, M
    Savas, MC
    Haznedaroglu, IC
    CANCER, 1997, 80 (03) : 518 - 519
  • [34] Acute promyelocytic leukemia in children
    Schaison, GS
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1998, 15 (03) : 203 - 206
  • [35] Pediatric Acute Promyelocytic Leukemia
    Kutny, Matthew
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 : 19 - 20
  • [36] Extramedullary acute promyelocytic leukemia
    Wiernik, PH
    DeBellis, R
    Muxi, P
    Dutcher, JP
    CANCER, 1996, 78 (12) : 2510 - 2514
  • [37] History of Acute Promyelocytic Leukemia
    Miguel A. Sanz
    Eva Barragán
    Clinical Hematology International, 2021, 3 (4) : 142 - 152
  • [38] ACUTE PROMYELOCYTIC LEUKEMIA IN CHILDREN
    CHAN, KW
    STEINHERZ, PG
    MILLER, DR
    MEDICAL AND PEDIATRIC ONCOLOGY, 1981, 9 (01): : 5 - 15
  • [39] MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
    FENAUX, P
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1993, 50 (02) : 65 - 73
  • [40] Treatment of Acute Promyelocytic Leukemia
    Miura, Yuji
    Suyama, Koichi
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (15): : 1471 - 1472